Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal

Lapatinib and lapatinib plus trastuzumab therapy versus

Radiotherapy as a tool to elicit clinically actionable signalling

Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Page 1526 – Cancer Therapy Advisor

Great Strides in Precision Medicine: Personalized Oncology

img_003.jpg

Cancers, Free Full-Text

Clinical management of cutaneous adverse events in patients on

Clinical signs, pathophysiology and management of skin toxicity

Association between efficacy and skin rash following treatment

Lapatinib and lapatinib plus trastuzumab therapy versus

Biomedicines, Free Full-Text

Future cancer research priorities in the USA: a Lancet Oncology

Lapatinib and lapatinib plus trastuzumab therapy versus